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Summary
Background: The Indian tuberculosis control programme is the second largest health programme in the world. Sustaining
this programme in India will require continued financial support, particularly for drugs and contractual personnel. In
addition, the costs for diagnosis, supervision and salaries for regular programme personnel need to be sustained.
Objective: To measure unit provider cost for treating patients with tuberculosis.
Methods: All government health facilities situated in one tuberculosis unit (TU) of Tiruvallur district were visited in order
to evaluate daily practice of TB diagnosis and treatment. We interviewed administrators in these health facilities to
gather data on modalities for diagnosis, treatment and monitoring of tuberculosis patients. In addition, relevant financial
records from all health facilities were scrutinised for data collection. The cost analysis was done for diagnosis, treatment
and monitoring of TB patients treated under DOTS programme in the year 2002 For this study only the recurrent cost
(not the capital cost) is considered, even though the programme puts in a lot of investment at the preparatory stage of
the programme e.g. upgrading of labs and drugs stores, microscopes, motorcycles etc. Cost incurred on smear microscopy,
chest X-ray and drugs were classified as direct cost. Indirect cost is calculated based on proportion of staff time for TB
care delivery and for supervision of TB services. The exchange rate at the time study was 1$=Rs 46.
Results: Unit cost for smear microscopy was estimated to be Rs 10/-; for radiography Rs 25/-; and drug cost for Category
I Rs 392/-; Category I with extension Rs 495/-; Category II Rs 729/-; Category II with extension Rs 832/- and Category
III Rs 277/-. Including other recurrent expenditures like salary, materials, and maintenance, the overall unit provider cost
to treat a TB patient was Rs 1587/- for Category I, Rs 1924/- for Category II and Rs 1417/- Category III.
Conclusion: TB inflicts considerable economic burden on the overall health system. This information is vital for policy
makers and planners to allocate adequate budget to the programme.
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INTRODUCTION
The Revised National Tuberculosis Control
Programme (RNTCP) of India is the second largest
programme in the world and it is integrated with
primary health care services1.  India has an extensive
network of primary health centres (PHCs) and they
are involved in all the public health programmes such
as immunization, reproductive and child health
programme, school health programme, tuberculosis
and malaria control etc., in addition to treatment of
minor ailments.
Information on the cost of providing health
services is essential for good planning and
management that leads to an efficient use of limited
resources2.  However literature on cost analysis of
health services in developing countries is scarce.
Various studies have reported the economic burden
posed by tuberculosis on TB patients and the
nation3-4.   However unit cost incurred for providing
care by the governmental health care system, which
includes costs of diagnostic tests, drugs and service
costs, has not been evaluated. In this study, we have
attempted to estimate unit cost in providing care to
TB patients.
MATERIAL  AND METHODS
Setting
Tamil Nadu has 29 districts each covering
populations ranging from 1.5 to 4.5 million. The
District TB Centre (DTC) is situated at the district
headquarters, with a District TB Officer (DTO)
as the overall manager of the TB programme in
Tuberculosis Research Centre (ICMR), Chennai
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the district.  At the sub-district level, there is one
TB Unit for every 500,000 population and
designated microscopy centres (DMC) for every
100,000 population. Within a district, there are
General Hospitals (GHs) at the district and taluk
levels, block primary health centres each catering
to 100,000 – 150,000 population, with 2-3
Primary Health Centres (PHC) within the
catchment area of a block PHC. The PHC, the
basic health unit caters to rural populations of
about 30,000. Within the administrative control
of the PHCs, there are sub-centres which cover
a population of 5,000, and these are the most
peripheral units of the governmental health delivery
system in rural areas.
India’s Revised National Tuberculosis
Control Programme (RNTCP), an adoption of the
internationally recommended Directly Observed
Treatment Short course (DOTS) strategy, focuses
on providing free quality sputum smear
microscopy for diagnosis as well as quality drugs
for treatment free of cost. This strategy also
provides decentralized treatment services close to
patients’ residence under direct observation with
the help of government health workers and
community volunteers.
Study area
This study was conducted in a
Tuberculosis Unit, covering a population of
580,000, of a rural district of Tamil Nadu
(Tiruvallur), where RNTCP has been in place since
May 1999.  In 2002 the case detection was 84%,
conversion rate 87%,  treatment success was 75%
and default rate was 15%.
Study design
Data collection
All the government health facilities, including sub-
centres, situated in this TB Unit were visited and
all records pertaining to the TB programme were
examined. The following information was
collected: staff salary, costs incurred for reagents,
drugs, maintenance, stationery and fuel etc.  Based
on the information collected, the following costs
were estimated:
• personnel cost, including supervision and
monitoring:
• cost of a drug regimen:
• cost of a sputum smear examination; and
• cost of a chest X-ray.
From these, we estimated the total cost for
management of a tuberculosis patient
A profile of the government health facilities
available, including microscopy centres, and the list
of health personnel involved in health care, was
collected. Out-patient attendance data of the year
2002, number of chest symptomatics identified,
number of sputum microscopy examinations
performed and number of TB patients diagnosed and
started on treatment in the above area, was collected.
Information on the various activities of the
health staff was collected. This included the time
spent on various field activities by the staff. On the
basis of proportion of time spent on TB patients for
diagnosis and treatment, staff costs were determined.
Medical officer screens all persons attending
Outpatient Department and selects the TB suspects.
For each TB suspect identified, he spends 5 minutes
for eliciting history of complaints and for ordering
of 3 sputum examinations. During 2nd visit he spends
10-15 minutes to scrutinize the smear results and
for eliciting history of previous Anti TB Treatment,
categorization, health education and for starting
treatment card. If patients default 2-4 hours are spent
for visiting patients’ house. For weekly review all
patients started on RNTCP regimen 1 hour is spent.
Every month 4-5 hours are spent for preparation of
monthly programme management report and
quarterly report.   Laboratory Technician spends 30%
of his time for TB work.
Type of cost calculated
Only financial costs were considered,
including costs associated with tuberculosis services
and those costs which vary with output levels.
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Variable costs shared or joint costs were calculated
using proportional time allocation (proportion of staff
time). Capital costs were not included in this study.
Following definitions were used to calculate the
costs
Cost: The value of resources used to produce
something, including a specific health service or a
set of services
Total cost: Total cost is sum of direct and
indirect costs.
Costs incurred on smear microscopy, chest
X-ray and drugs were classified as direct cost.
Indirect cost was calculated based on proportion of
staff time for TB care delivery and for supervision
of TB services. The prevailing exchange rate at the
time of study was 1$=Rs 46.
Unit Cost: A unit cost is a simple average
or the cost per unit of outcome (i.e. is an indicator
of efficiency). The basic calculation of a unit cost is
average cost per patient treated:
               Total cost for tuberculosis services
Unit Cost =
                 Total tuberculosis patients registered
                 for treatment
RESULTS
The profile of health facilities, the staff
pattern and the case finding activities of the TB
control programme are described in Table 1. There
were 15 Primary Health Centres, 2 Government
Hospitals,  12 centres offering microscopy
facilities and 120 treatment centres. The health
personnel available for tuberculosis treatment in
this area were 48 Medical Officers (MOs), 12
Laboratory Technicians (LTs), 117 Health Visitors
(HV)/ Staff Nurse/ Health Assistant/Multipurpose
Health Supervisor, 102 Multi-Purpose Health
Worker, 1 Senior Treatment Supervisors (STS)
and 1 Senior Tuberculosis Laboratory Supervisor
(STLS).
In the year 2002, number of chest
symptomatics examined were 5717 and 892 TB
patients were detected. For these patients the unit
cost was estimated, including cost for follow-up
sputum microscopy.
The unit costs for tests done for TB
diagnosis, anti TB treatment drug boxes and staff
salary are given in Table 2. The unit cost for sputum
smear microscopy was Rs 10/- and  for radiography
Rs 25/-.  The cost of drugs for category I
Rs 392/-; category I with extension Rs 495; category
II Rs 729/-; category II with extension Rs 832/- and
Health facilities 
PHCs 
Government Hospitals 
Microscopy centres 
Treatment centres 
 
         15 
           2 
         12 
       120 
Health personnel 
Medical Officers 
LTs 
HV/Staff nurses/Health assistants/Multipurpose health 
supervisors 
Multi purpose health workers 
Anganwadi workers 
STS 
STLS 
 
          48 
          12 
        117 
 
        102 
     1 047 
           1 
           1 
Case finding 
Total outpatients 
Chest symptomatics 
Tuberculosis Patients  
 
625696 
5717 (1%) 
892 (0.1%) 
 
Table 1: Profile of health system and tuberculosis case finding in one TU of Tiruvallur district of Tamil Nadu
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category III Rs 277/-.
The proportion of time spent for TB services
by different health personnel ranges from 100% for
personnel working in the district TB centre to <10%
for health visitors working in the field. Laboratory
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technicians spend 30% of their working time for TB
services. Cost for personnel for complete treatment
of a patient was estimated as follows: Medical Officer
Rs 116/-, Laboratory Technician Rs 54/-, STS Rs
129/-, STLS Rs 183/-, Health visitor Rs 187/-,
Supporting staffs (Nurse, Pharmacist, Assistant, 
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Fig. 2: The proportion of cost spent for diagnosis,
drugs and personnel to treat a TB patient
Cost     Rs 
For one smear examination 
      one radiograph 
    10 
    25 
For regimen 
Category I 
Category I (with extension) 
Category II 
Category II (with extension) 
Category III 
 
  392 
  495 
  729 
  832 
  277 
For personnel  
Medical Officer 
Laboratory Technician 
Health visitor 
Supporting staff 
DTC 
STS 
STLS 
 
 116 
   54 
 187 
 161 
 284 
 129 
 183 
 
Personnel
70%
Drugs
25%
Diagnosis 
5%
Fig. 1: Unit provider cost ( direct  and indirect ) to treat a tuberculosis patient under RNTCP.
Table 2: Unit cost for tests, drugs and personnel
for tuberculosis treatment in one TU of
Tiruvallur district of Tamil Nadu
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Menial staff, Watchman) Rs 161/- and for all the
DTC staff together (MO, HV, Pharmacist,
Radiographer, Assistant, Hospital worker, Sanitary
worker, Lab Technician and Driver) Rs 284/-.
Thus, the overall (direct and indirect) unit
provider cost to treat a TB patient was Rs 1587/- (Rs
1114 + Rs 473) for category I, Rs 1924/- (Rs 1114 +
Rs 810) for category II and Rs 1417/- (Rs 1114 + Rs
303) category III (Figure 1). Of the overall unit provider
cost, about 70% was spent on personnel, 25% on drugs
and 5% on diagnosis (Figure 2).
DISCUSSION
The main finding of the present study is that
the overall unit provider cost per patient treated under
national TB control programme in this area ranged from
Rs.1400/- ($30) to Rs.2000/- ($43) according to the
category of treatment. For this calculation, the costs
of the drugs and investigations and the salaries of staff
(shared costs) were included.  Similar findings were
reported in a WHO report from India in 2004 on cost
and cost effectiveness of public private mix, which
found that the  average cost per patient successfully
treated to be around US$30-40 when only public sector
costs were considered5. However, this figure was
considered to be low by international standards.
Similarly in an earlier study conducted prior to RNTCP
implementation, the cost of health services provided
at PHC to diagnose a TB patient was Rs 1350/-2.
Of the overall unit provider cost of
Rs 1400/- ($30), around 70% of the costs were spent
on personnel salaries etc and around 25% on drugs.
Similarly, a study from Thailand showed that even
though the costs of drugs used in 3 short – course
regimens were lower than the cost of the standard
regimen, from the provider perspective, the total
provider costs were ‘the highest due to the highest
routine service costs as a cost of providing care is
not limited only to drug costs but also includes other
services costs6.  One of the ways of reducing costs
for curative care suggested in an earlier report was
to substitute the better-paid medical officers by lower
paid paramedical staff as the TB control programme
is integrated with the primary health care service
and is decentralized up to the community (WHO
document)8.  But in our study, we observed that the
cost spent on personnel was distributed among
various group of workers and this suggestion may
not be applicable to the existing set up.
Cure of infectious TB patients is, currently,
the best form of prevention. The DOTS strategy
has shown to increase the successful treatment
outcomes of TB treatment from below 50% to over
80%. Ravindra Dholakia reported that if the Indian
government spent even $200 million per year on
effective DOTS implementation, the tangible benefit
to Indian economy would be worth at least $750
million per year4.
Our estimates demonstrate that the adoption
of DOTS by the TB control programme is cost
effective as DOTS achieves the lowest cost per person
treated compared to the estimated costs reported earlier2
and the greatest effectiveness with regards to lives
saved and relapses avoided. In particular, avoiding
relapse has potentially important public health
implications, due to the reduction of cases of TB with
subsequent reduction of provider cost associated with
relapse. One of the major benefits of effective treatment
is the prevention of further transmission. A study done
in Indonesia showed that every dollar invested on TB
control can give a return of at least $55 over 20 years7.
The World Bank has hailed DOTS as “one of the most
cost effective interventions available”8.  Country studies
in the early 1990s from Malawi, Mozambique and
Tanzania showed the cost of TB interventions ranging
from $19-52 per life saved. However drug costs were
up to four times higher at that time. Today the DOTS
drug package can be purchased for as little as $109.
This means that investing in TB control will immediately
save lives,. Over time, TB control will also “turn a
profit” as it reduces the disease burden on society.
In 1997, we undertook a study to measure
the socio economic impact of TB on patients and their
families3.  Based on the findings of the study, projections
were made on economic burden caused by TB in India.
It was estimated to be more than Rs 13000/-crores
($3 billion) per year including loss of wages incurred
by patients an account of TB. The patients spent more
than Rs 645/- crores ($180 million) on private TB care10.
With the DOTS strategy, more patients are getting
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diagnosed early, sputum conversion occurs early and
8 out of 10 patients started on treatment are cured by
6-months8. This means that the number of workdays
lost will be reduced, which will reduce the economic
burden to the country.
Limitations of the study
The costs have been estimated only for out
patient care and do not include cost incurred for
inpatient care. Another major limitation of this study
was that capital costs were not included in estimation
of the cost. We have not included the expenditure
for incentives provided and the time cost for the
community volunteers by the programme, as this
has not been the practice in the study area. Thus,
ours may be an under estimate.
CONCLUSION
To conclude, the provider cost is
considerable for management of TB patients
and inflicts considerable economic burden on
the overall health system. The overall unit
provider cost per patient treated under
national TB control programme in the study
area ranged from Rs1400/- to 2000/- (US $ 31-44)
according to the category of treatment. The cost
for drugs is about 25% and the cost of personnel
around 70%. The policy makers and planners
must accord TB control a high priority and allocate
adequate resources, both human and financial, to
ensure effective implementation of the DOTS
strategy. This will prevent deaths due to TB,
promote economic development, reduce ill health
and enhance the quality of life of people in India.
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